AR114732A1 - Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco - Google Patents
Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármacoInfo
- Publication number
- AR114732A1 AR114732A1 ARP190102617A ARP190102617A AR114732A1 AR 114732 A1 AR114732 A1 AR 114732A1 AR P190102617 A ARP190102617 A AR P190102617A AR P190102617 A ARP190102617 A AR P190102617A AR 114732 A1 AR114732 A1 AR 114732A1
- Authority
- AR
- Argentina
- Prior art keywords
- trifluoromethyl
- inhibitor
- formation
- cathepsin
- drug antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere en particular a un inhibidor de catepsina S para la utilización en un método para reducir o impedir la formación de anticuerpos antifármaco (ADA) contra un agente terapéutico en un sujeto que está recibiendo un tratamiento con dicho agente terapéutico. Reivindicación 20: Inhibidor de catepsina S para la utilización, un método o un kit según cualquiera de las reivindicaciones 1 a 19, en el que el inhibidor de catepsina S es: (1-ciano-ciclopropil)-amida del ácido (2S,4R)-4-[4-(1-metil-1H-pirazol-4-il)-2-trifluorometil-bencenosulfonil]-1-(1-trifluorometil-ciclopropanocarbonil)-pirrolidín-2-carboxílico, o (1-ciano-ciclopropil)-amida del ácido (2S,4R)-4-[4-(5-metil-tetrazol-2-il)-2-trifluorometil-bencenosulfonil]-1-(1-trifluorometil-ciclopropanocarbonil)-pirrolidín-2-carboxílico; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18195251 | 2018-09-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR114732A1 true AR114732A1 (es) | 2020-10-07 |
Family
ID=63787710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190102617A AR114732A1 (es) | 2018-09-18 | 2019-09-17 | Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210315863A1 (es) |
EP (1) | EP3852880A1 (es) |
JP (1) | JP7438198B2 (es) |
KR (1) | KR20210061344A (es) |
CN (1) | CN112839716A (es) |
AR (1) | AR114732A1 (es) |
AU (1) | AU2019344567A1 (es) |
CA (1) | CA3112032A1 (es) |
CR (1) | CR20210143A (es) |
IL (1) | IL281444A (es) |
MA (1) | MA53635A (es) |
MX (1) | MX2021003127A (es) |
SG (1) | SG11202102471XA (es) |
WO (1) | WO2020058297A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110573528B (zh) * | 2017-03-29 | 2023-06-09 | 豪夫迈·罗氏有限公司 | 针对共刺激性tnf受体的双特异性抗原结合分子 |
US20210332122A1 (en) * | 2020-04-17 | 2021-10-28 | Cedars-Sinai Medical Center | Dysregulation of covid-19 receptor associated with ibd |
WO2023245008A1 (en) * | 2022-06-13 | 2023-12-21 | Genentech, Inc. | Methods of delaying or preventing the onset of alzheimer's disease using crenezumab |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
US20070141059A1 (en) * | 2003-12-11 | 2007-06-21 | Axys Pharmaceuticals, Inc. | Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
US9321838B2 (en) * | 2006-04-10 | 2016-04-26 | Fusion Antibodies Limited | Therapy targeting cathepsin S |
CN101687915B8 (zh) | 2007-04-03 | 2018-08-03 | 安进研发(慕尼黑)股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
JP5518997B2 (ja) * | 2009-04-20 | 2014-06-11 | エフ.ホフマン−ラ ロシュ アーゲー | カテプシン阻害薬としてのプロリン誘導体 |
HUE055284T2 (hu) | 2011-02-10 | 2021-11-29 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US8796471B2 (en) * | 2011-11-11 | 2014-08-05 | Hoffmann-La Roche Inc. | Process for the preparation of proline derivatives |
CA2859928A1 (en) * | 2012-02-17 | 2013-08-22 | F. Hoffmann-La Roche Ag | Novel pyrrolidine derivatives |
WO2016034602A1 (en) * | 2014-09-05 | 2016-03-10 | F. Hoffmann-La Roche Ag | Solid forms of (2s,4r)-4-[4-(1-methyl-1h-pyrazol-4-yl)-2-trifluoromethyl-benzenesulfonyl]-1-(1-trifluoromethyl-cyclopropanecarbonyl)-pyrrolidine-2-carboxylic acid (1-cyano-cyclopropyl)-amide |
MX2018004157A (es) | 2015-10-07 | 2019-04-01 | F Hoffmann La Roche Ag | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador. |
PL3387015T3 (pl) * | 2015-12-09 | 2022-02-14 | F. Hoffmann-La Roche Ag | Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych |
RS59938B1 (sr) * | 2016-02-26 | 2020-03-31 | Hoffmann La Roche | Novi derivati pirolidina |
AU2018359506A1 (en) | 2017-11-01 | 2020-04-23 | F. Hoffmann-La Roche Ag | Combination therapy with targeted OX40 agonists |
-
2019
- 2019-09-17 AR ARP190102617A patent/AR114732A1/es unknown
- 2019-09-18 CR CR20210143A patent/CR20210143A/es unknown
- 2019-09-18 WO PCT/EP2019/074918 patent/WO2020058297A1/en active Search and Examination
- 2019-09-18 JP JP2021515158A patent/JP7438198B2/ja active Active
- 2019-09-18 MA MA053635A patent/MA53635A/fr unknown
- 2019-09-18 SG SG11202102471XA patent/SG11202102471XA/en unknown
- 2019-09-18 KR KR1020217007922A patent/KR20210061344A/ko unknown
- 2019-09-18 CA CA3112032A patent/CA3112032A1/en active Pending
- 2019-09-18 AU AU2019344567A patent/AU2019344567A1/en active Pending
- 2019-09-18 CN CN201980067371.2A patent/CN112839716A/zh active Pending
- 2019-09-18 EP EP19768832.8A patent/EP3852880A1/en active Pending
- 2019-09-18 MX MX2021003127A patent/MX2021003127A/es unknown
-
2021
- 2021-03-11 IL IL281444A patent/IL281444A/en unknown
- 2021-03-18 US US17/206,044 patent/US20210315863A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN112839716A (zh) | 2021-05-25 |
EP3852880A1 (en) | 2021-07-28 |
JP7438198B2 (ja) | 2024-02-26 |
CR20210143A (es) | 2021-04-21 |
US20210315863A1 (en) | 2021-10-14 |
TW202023542A (zh) | 2020-07-01 |
MX2021003127A (es) | 2021-05-14 |
AU2019344567A1 (en) | 2021-03-25 |
SG11202102471XA (en) | 2021-04-29 |
MA53635A (fr) | 2022-04-13 |
WO2020058297A1 (en) | 2020-03-26 |
CA3112032A1 (en) | 2020-03-26 |
IL281444A (en) | 2021-04-29 |
KR20210061344A (ko) | 2021-05-27 |
JP2022501356A (ja) | 2022-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR114732A1 (es) | Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco | |
CO2019002556A2 (es) | Composición farmacéutica | |
DOP2022000183A (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
BR112018015718A2 (pt) | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) | |
CO5640076A2 (es) | Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimiento | |
PE20121396A1 (es) | Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol | |
AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
AR040248A1 (es) | Farmaco para el tratamiento de la vejiga hiperactiva | |
AR119318A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
MX2021000778A (es) | Metodos de tratamiento y prevencion de la enfermedad de alzheimer. | |
MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
PE20190972A1 (es) | Combinacion de agonistas de fxr | |
CL2021002217A1 (es) | Composición farmacéutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda | |
BR112019009726A2 (pt) | terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica | |
MX2021002322A (es) | Nuevos metodos. | |
MX2021013491A (es) | Nuevas endolisinas de gardnerella y usos de las mismas. | |
CL2020003143A1 (es) | Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
WO2021262562A3 (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof | |
WO2021048779A3 (en) | Modified dosing of vegf inhibitors for ophthalmic use | |
AR127533A1 (es) | INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS | |
AR127966A1 (es) | Formulaciones tópicas de inhibidores de pi3k-delta | |
CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
BR112023017689A2 (pt) | Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |